Taken together, these results suggest that KLF4 is most likely expressed in CD133+ subpopulation and DLD-1-derived spheroid cells, which enriched CSCs, challenging the previous conclusion of that KLF4 functions as a tumor suppressor in colon cancer progression. Here, KLF4 is linked to colonic neoplasm.